SE168308C1 - - Google Patents
Info
- Publication number
- SE168308C1 SE168308C1 SE168308DA SE168308C1 SE 168308 C1 SE168308 C1 SE 168308C1 SE 168308D A SE168308D A SE 168308DA SE 168308 C1 SE168308 C1 SE 168308C1
- Authority
- SE
- Sweden
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE168308T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE168308C1 true SE168308C1 (es) |
Family
ID=41958801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE168308D SE168308C1 (es) |
Country Status (1)
| Country | Link |
|---|---|
| SE (1) | SE168308C1 (es) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
| WO2014029841A1 (en) | 2012-08-23 | 2014-02-27 | Cardiolynx Ag | Extended release compositions of an aminoalkyl nitrate |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| WO2016135263A1 (en) | 2015-02-27 | 2016-09-01 | Armin Scherhag | No donors for the treatment of stress-induced pulmonary haemorrhage in animals |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
-
0
- SE SE168308D patent/SE168308C1/xx unknown
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| WO2014029841A1 (en) | 2012-08-23 | 2014-02-27 | Cardiolynx Ag | Extended release compositions of an aminoalkyl nitrate |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| WO2016135263A1 (en) | 2015-02-27 | 2016-09-01 | Armin Scherhag | No donors for the treatment of stress-induced pulmonary haemorrhage in animals |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| EP4470609A2 (en) | 2019-01-18 | 2024-12-04 | Astrazeneca AB | Pcsk9 inhibitors and methods of use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1052820A (en) | Aromatic ketones having cardiovascular activity | |
| US20160102074A1 (en) | Substituted amide compounds | |
| US20180008558A1 (en) | Extended release compositions of an aminoalkyl nitrate | |
| WO2016135263A1 (en) | No donors for the treatment of stress-induced pulmonary haemorrhage in animals | |
| SE168308C1 (es) |